Abstract
COVID-19 guideline recommendations suggest to expand the prophylactic use of colony-stimulating factors in patients with cancer with intermediate to high risk for febrile neutropenia (FN). We evaluated the cost-effectiveness of primary prophylaxis (PP) with Sandoz biosimilars filgrastim and pegfilgrastim patients with breast cancer with intermediate risk of FN compared with secondary prophylaxis (SP) in France, Germany, and Austria.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
